Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial-Reference-Cited by-同舟云学术

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Published:2010-01 Issue:1 Volume:11 Page:55-65
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Albain Kathy S,Barlow William E,Shak Steven,Hortobagyi Gabriel N,Livingston Robert B,Yeh I-Tien,Ravdin Peter,Bugarini Roberto,Baehner Frederick L,Davidson Nancy E,Sledge George W,Winer Eric P,Hudis Clifford,Ingle James N,Perez Edith A,Pritchard Kathleen I,Shepherd Lois,Gralow Julie R,Yoshizawa Carl,Allred D Craig,Osborne C Kent,Hayes Daniel F

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

2. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients;Habel;Breast Cancer Res,2006

3. A gene-expression signature as a predictor of survival in breast cancer;Van de Vijver;N Engl J Med,2002

4. Gene expression profiling of breast cancer: a new tumor marker;Van't Veer;J Clin Oncol,2005

5. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer;Paik;J Clin Oncol,2006

Cited by 1208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer;The Breast;2024-10

2. Reporting Hormone Receptor Expression in Breast Carcinomas: Which Method has the Highest Prognostic Power and What Should be the Optimal Cut-off Value?;International Journal of Surgical Pathology;2024-09-08

3. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer;Journal of Clinical Oncology;2024-09-01

4. Closing the gap: prognostic and predictive biomarker validation for personalized care in a Latin American hormone-dependent breast cancer cohort;The Oncologist;2024-08-08

5. Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period;The Breast;2024-08